IN2014CN04498A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04498A
IN2014CN04498A IN4498CHN2014A IN2014CN04498A IN 2014CN04498 A IN2014CN04498 A IN 2014CN04498A IN 4498CHN2014 A IN4498CHN2014 A IN 4498CHN2014A IN 2014CN04498 A IN2014CN04498 A IN 2014CN04498A
Authority
IN
India
Prior art keywords
domain
sequence
terminus
amino acid
protein
Prior art date
Application number
Other languages
English (en)
Inventor
Jerzy Szczepan Pieczykolan
Sebastian Pawlak
Michal Szymanik
Anna Maria Pieczykolan
Bartlomiej Maciej Zerek
Piotr Rózga
Albert Robert Jaworski
Kaminska Malgorzata Izabela Teska
Original Assignee
Adamed Sp Zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo
Publication of IN2014CN04498A publication Critical patent/IN2014CN04498A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN4498CHN2014 2011-11-28 2012-11-28 IN2014CN04498A (show.php)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL397167A PL397167A1 (pl) 2011-11-28 2011-11-28 Przeciwnowotworowe bialko fuzyjne
PCT/IB2012/056806 WO2013080147A2 (en) 2011-11-28 2012-11-28 Anticancer fusion protein

Publications (1)

Publication Number Publication Date
IN2014CN04498A true IN2014CN04498A (show.php) 2015-09-11

Family

ID=47561689

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4498CHN2014 IN2014CN04498A (show.php) 2011-11-28 2012-11-28

Country Status (18)

Country Link
US (1) US20150044162A1 (show.php)
EP (1) EP2785362A2 (show.php)
JP (1) JP2015500228A (show.php)
KR (1) KR20140097529A (show.php)
CN (1) CN103974711A (show.php)
AU (1) AU2012345494A1 (show.php)
BR (1) BR112014012808A2 (show.php)
CA (1) CA2856480A1 (show.php)
EA (1) EA201491049A1 (show.php)
HK (1) HK1201727A1 (show.php)
IL (1) IL232743A0 (show.php)
IN (1) IN2014CN04498A (show.php)
MX (1) MX2014006369A (show.php)
PH (1) PH12014501083A1 (show.php)
PL (1) PL397167A1 (show.php)
SG (1) SG11201402312WA (show.php)
WO (1) WO2013080147A2 (show.php)
ZA (1) ZA201404667B (show.php)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2970487T (lt) 2013-03-12 2020-05-11 Molecular Templates, Inc. Citotoksiniai baltymai, apimantys tikslinių ląstelių rišimosi sritis ir shiga toksino subvienetų sritis, skirtas selektyviam tam tikrų rūšių ląstelių žudymui
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
EP3575312A1 (en) 2014-01-27 2019-12-04 Molecular Templates, Inc. De-immunized shiga toxin a subunit effector polypeptides for applications in mammals
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
JP6935195B2 (ja) * 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素aサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
CA2947048C (en) 2014-06-11 2023-10-17 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
CN108064247B (zh) 2015-02-05 2022-06-03 分子模板公司 包含志贺毒素a亚基效应物区域的多价cd20结合分子及其富集组合物
WO2016127346A1 (zh) * 2015-02-11 2016-08-18 四川大学华西医院 一种肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
CN106380521B (zh) 2015-07-02 2020-12-29 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
KR101732126B1 (ko) 2015-11-05 2017-05-02 한국생명공학연구원 췌장암 치료용 융합 단백질 및 이의 용도
PL233352B1 (pl) * 2016-09-15 2019-10-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe białko fuzyjne
EP3551645A1 (en) 2016-12-07 2019-10-16 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
CN106632680A (zh) * 2016-12-27 2017-05-10 上海交通大学 植物体系表达人源化抗agr2单克隆抗体18a4的质粒构建
JP7082424B2 (ja) 2017-01-25 2022-06-08 モレキュラー テンプレーツ,インク. 脱免疫化された志賀毒素aサブユニットエフェクター及びcd8+t細胞エピトープを含む細胞標的化分子
WO2019173478A2 (en) * 2018-03-06 2019-09-12 The Johns Hopkins University Methods of treating or preventing cancer with an agent that depletes tregs and a checkpoint inhibitor
MX2019009726A (es) 2018-04-17 2020-02-05 Molecular Templates Inc Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.
WO2020234498A2 (es) * 2019-05-15 2020-11-26 Universidad De Granada Terapia génica con los genes hokd y ldrb para el tratamiento del cáncer
CN113354738B (zh) * 2020-03-05 2022-09-09 绍兴德方华生物技术有限公司 融合毒素VEGF165b/mGEL及其编码基因与应用
IL300701A (en) * 2020-08-17 2023-04-01 Atb Therapeutics Immunotoxin-containing immunotoxin-containing or renase
CN114681599B (zh) * 2020-12-31 2024-07-02 中国科学院上海药物研究所 一种阳离子脂质体疫苗及其制备方法和用途
EP4382606A4 (en) * 2021-08-06 2025-11-05 Kao Corp NUCLEIC ACID STRUCTURE INVOLVING SNARE PROTEINS
CN117384859B (zh) * 2023-12-13 2024-03-22 北京翊博生物集团有限公司 一种树突状细胞来源的外泌体的制备方法及应用
CN118792375B (zh) * 2024-06-25 2025-09-23 华南农业大学 一种具有补肾壮阳功效的瓜蒌多肽及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69635480T2 (de) 1995-06-29 2006-08-17 Immunex Corp., Thousand Oaks Apoptosis induzierendes cytokin
AU2001238501A1 (en) 2000-02-16 2001-08-27 Bechtel Bwxt Idaho, Llc Selective destruction of cells infected with human immunodeficiency virus
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
CN1257187C (zh) * 2003-10-22 2006-05-24 上海恰尔生物技术有限公司 钙网蛋白-肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
BRPI0318594B8 (pt) 2003-11-03 2021-05-25 Beijing Sunbio Biotech Co Ltd proteína recombinante que possui um efeito anticâncer, seu gene de codificação, seu uso, medicamento para tratar cânceres, vetor de expressão e microrganismo transgênico
US7252993B2 (en) 2004-03-12 2007-08-07 Battelle Energy Alliance, Llc Plasmids encoding therapeutic agents
PL3006456T3 (pl) 2005-07-29 2019-05-31 The Government Of The Secretary Of Health And Human Services Zmutowane egzotoksyny pseudomonas o zmniejszonej antygenowości
PT1915626E (pt) 2005-08-16 2012-02-03 Genentech Inc Sensibilidade da apoptose a apo2l/trail por ensaio de expressão de galnac-t14 em células/tecidos
EP2079840A4 (en) 2006-10-30 2010-06-30 Viventia Biotech Inc IMMUNOTOXIN FUSIONS COMPRISING PROTEASEPLATABLE LINKER-ASSOCIATED ANTIBODY FRAGMENT AND PLANT TOXIN
SG163558A1 (en) 2006-12-29 2010-08-30 Osprey Pharmaceuticals Usa Inc Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
WO2009094634A1 (en) * 2008-01-24 2009-07-30 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same
CL2009001191A1 (es) 2008-05-14 2010-07-02 Genentech Inc Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin.
US8039437B2 (en) * 2008-06-30 2011-10-18 The Trustees Of The University Of Pennsylvania Fn14/TRAIL fusion proteins

Also Published As

Publication number Publication date
WO2013080147A3 (en) 2014-02-13
JP2015500228A (ja) 2015-01-05
PH12014501083A1 (en) 2014-08-04
CN103974711A (zh) 2014-08-06
MX2014006369A (es) 2014-07-09
EP2785362A2 (en) 2014-10-08
BR112014012808A2 (pt) 2019-09-24
US20150044162A1 (en) 2015-02-12
HK1201727A1 (en) 2015-09-11
KR20140097529A (ko) 2014-08-06
EA201491049A1 (ru) 2014-10-30
AU2012345494A1 (en) 2014-07-10
SG11201402312WA (en) 2014-06-27
CA2856480A1 (en) 2013-06-06
IL232743A0 (en) 2014-07-31
ZA201404667B (en) 2015-09-30
PL397167A1 (pl) 2013-06-10
WO2013080147A2 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
IN2014CN04498A (show.php)
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
PH12013500714A1 (en) Anticancer fusion protein
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
IN2014KN01715A (show.php)
MX352796B (es) Proteina de fusion anticancerigena.
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
NZ630536A (en) Therapeutic agent or prophylactic agent for dementia
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
PH12013501970A1 (en) Anticancer fusion protein
WO2010011952A3 (en) Flip death effector domain derived peptides for inducing autophagy
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
MX380750B (es) Composición farmacéutica para tratar y/o prevenir el cáncer.
PH12014502198A1 (en) Osteoprotegerin derived composition and use thereof
GB201019467D0 (en) Therapeutic agent
UA108911C2 (xx) Протираковий злитий протеїн
WO2013052168A3 (en) Detection aib1-delta 4 protein
TH159052A (th) ฟิวชั่นโปรตีนต้านมะเร็ง (Anticancer fusion protein)